FindTrial
Sign In

Brown adipose tissue and bile acids

The role of bile acids in human brown adipose tissue metabolism - BAT and bila acids

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2013-002512-27-NL
Enrollment
Unknown
Registered
2013-10-23
Start date
2013-11-25
Completion date
Unknown
Last updated
2013-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

Trade Name: Chenodeoxycholic acid, Xenbilox Product Name: Xenbilox Pharmaceutical Form: Capsule, hard INN or Proposed INN: Xenbilox CAS Number: 474-25-9 Other descriptive name: CHENODEOXYCHOLIC ACID C

Sponsors

Maastricht University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Caucasians - Age: 18-30 years - Gender: male and female (females only on a specific oral contraceptive pill; microgynon 30 or levonorgestrel/ethinylestradiol) - BMI: 18-25 kg/m2 - Good general health Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 18 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Psychologically unstable subjects (as judged by the treating medical specialist) - Subjects with mental retardation (as judged by the treating medical specialist) - Subjects with severe behavior disorders (as judged by the treating medical specialist) - Pregnancy or lactation - The use of the following medication one month before the study is an exclusion criterium; ß-blockers, ursodeoxycholic acid, bile acid sequestrants, antacids - Participation in an intensive weight-loss program or vigorous exercise program during the last year before the start of the study - Abuse of drugs and/or alcohol - Severe diabetes which requires application of insulin or patients with diabetes-related complications - Surgery of the gastro-intestinal tract (only appendectomy is allowed) - Previous ERCP with papillotomy - History of cholesystectomy or disease of the gallbladder, biliary system and/or liver - Hyperthyroidism or hypothyroidism - BMI > 25 kg/m2 - Participation in earlier research or medical examinations that included PET/CT scanning

Design outcomes

Primary

MeasureTime frame
Main Objective: To study the effect of bile acids on brown adipose tissue activity and energy expenditure in humans.;Secondary Objective: The effect of bile acids on - skin temperature - body core temperature - skin perfusion - mitochondrial respiration in skeletal muscle - browning of white adipocytes;Primary end point(s): - Brown adipose tissue activity - Energy expenditure;Timepoint(s) of evaluation of this end point: Directly after the measurements—

Secondary

MeasureTime frame
Secondary end point(s): - skin temeprature - body core temperature - skin perfusion - mitochondrial respiration in myocytes - ' browning' of white fat;Timepoint(s) of evaluation of this end point: Directly after measurements—

Countries

Netherlands

Contacts

Public ContactEvie Broeders

Maastricht University

e.broeders@maastrichtuniversity.nl0031433884260

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026